N-羟基磺基琥珀酰亚胺-4-叠氮基苯甲酸酯 | 199804-22-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-羟基磺基琥珀酰亚胺-4-叠氮基苯甲酸酯
• 英文名称: 3-Pyrrolidinesulfonic acid, 1-[(4-azidobenzoyl)oxy]-2,5-dioxo-
• 英文别名: 1-(4-azidobenzoyl)oxy-2,5-dioxopyrrolidine-3-sulfonic acid
• CAS: 199804-22-3
• 化学式: C11H8N4O7S
• 分子量: 340.27
• InChiKey: ULSXSHDMKGETEK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  141
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• [EN] MITOCHONDRIAL MODULATION TO IMPROVE METABOLIC SYNDROME DURING AGING<br/>[FR] MODULATION MITOCHONDRIALE POUR AMÉLIORER LE SYNDROME MÉTABOLIQUE PENDANT LE VIEILLISSEMENT
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2021034548A1

  公开（公告）日：2021-02-25

  Compounds, compositions and methods are provided for mitochondrial modulation. The subject mitochondrial modulator compounds generally include a head group linked to a charged moiety. In certain cases, the head group is a heterocyclic or a heteroaryl group. Aspects of the subject methods include a method of modulating mitochondria. Aspects of the subject methods include treating a subject having a metabolic syndrome-related disease or a symptom thereof by administering to the subject a therapeutically effective amount of a subject compound. In certain cases, the disease is selected from hyperlipidemia, type 2 diabetes, fatty liver disease, obesity, cardiovascular disease and stroke. In certain cases, the symptom is selected from abdominal obesity, insulin resistance, hyperinsulinemia, high levels of blood fats, increased blood pressure, and elevated serum lipids.

  提供了用于线粒体调节的化合物、组合物和方法。所述线粒体调节剂化合物通常包括与带电基团相连的头基团。在某些情况下，头基团是杂环或杂芳基团。所述方法的方面包括调节线粒体的方法。所述方法的方面包括通过向患有代谢综合征相关疾病或其症状的患者施用所述化合物的治疗有效量来治疗患者。在某些情况下，该疾病选自高脂血症、2型糖尿病、脂肪肝病、肥胖症、心血管疾病和中风。在某些情况下，该症状选自腹部肥胖、胰岛素抵抗、高胰岛素血症、高血脂水平、高血压和血清脂质升高。
• FLUORESCENT PROBES FOR QUANTIFICATION OF DNA DAMAGE AND REPAIR
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US20210147932A1

  公开（公告）日：2021-05-20

  Probes, methods and kits for detecting and measuring abasic (AP) sites in a nucleic acid are provided. Aspects of the methods include determining glycosylase enzyme activity. Further provided herein are methods of quantifying AP sites in genomic DNA, and quantifying the amount of DNA damage. The subject probes include a fluorophore linked to an alpha nucleophile that reacts with the AP site of the nucleic acid to produce a highly fluorescent conjugate.

  提供用于检测和测量核酸中脱嘌呤（AP）位点的探针、方法和试剂盒。该方法的一些方面包括确定醇基化酶酶活性。此外，还提供了一种在基因组DNA中定量AP位点和DNA损伤量的方法。所述探针包括与α亲核试剂相连的荧光团，该试剂与核酸的AP位点发生反应，产生高度荧光的共轭物。
• Phosphoprotein affinity resins and methods for making and using the same
  申请人：Tchaga Simeonov Grigoriy

  公开号：US20060079671A1

  公开（公告）日：2006-04-13

  Phosphorylated protein (i.e., phosphoprotein) affinity resins and methods for making and using the same are provided. The subject resins include a substrate bonded to aspartate-based tetradentate ligand/metal ion complexes, where the tetradentate ligand/metal ion complexes have high specificity for phosphorylated amino acids. The subject resins find use in a variety of different applications, including phosphoprotein enrichment applications. Also provided are kits and systems that include the subject resins.

  提供了磷酸化蛋白（即磷蛋白）亲和树脂及其制备和使用方法。所述树脂包括与以天冬氨酸为基础的四齿配体/金属离子复合物结合的基质，其中四齿配体/金属离子复合物对磷酸化氨基酸具有很高的特异性。所述树脂可用于各种不同的应用中，包括磷蛋白富集应用。还提供了包括所述树脂的试剂盒和系统。
• Pulmonary delivery for bioconjugation
  申请人：CONJUCHEM, INC.

  公开号：US20040156859A1

  公开（公告）日：2004-08-12

  Methods of and compositions for pulmonary delivery of therapeutic agents which are capable of forming covalent bonds with a site of interest or which have formed a covalent bond with a pulmonary solution protein are disclosed. Therapeutic agents useful in the invention include wound healing agents, antibiotics, anti-inflammatories, anti-oxidants, anti-proliferatives, immunosupressants, anti-infective and anti-cancer agents.

  本发明公开了一种可与感兴趣的部位形成共价键或已与肺溶液蛋白形成共价键的治疗剂的肺部输送方法和组成物。本发明中有用的治疗剂包括伤口愈合剂、抗生素、抗炎剂、抗氧化剂、抗增殖剂、免疫抑制剂、抗感染和抗癌剂。
• IMMUNOLOGICAL REAGENTS AND USES THEREFOR
  申请人：THE UNIVERSITY OF MELBOURNE

  公开号：US20150166542A1

  公开（公告）日：2015-06-18

  The present invention provides a ligand which binds to MR1 wherein said binding results in binding of the MR1 to MAIT cells.

  本发明提供了一种能够与MR1结合的配体，其中该结合导致MR1与MAIT细胞的结合。